John Gribben - CAR-T Therapy
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
EHA 2024 - Prof John Gribben speaks to Deborah Henderson about CLL Clinical Trials
Professor John G. Gribben: iwCLL 2017
Professor John Gribben - Treating patients with chronic lymphocytic leukaemia (CLL)
ASH 2019 Interview - Prof John Gribben - precision medicine & genetic testing
Prof. John Gribben, London (UK): Introduction
ASH 2019 Interview - Prof John Gribben and Deborah Sims - Overview of CLL treatment
Prof John Gribben: Highlights of CLL - ICML 2017
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 1)
Prof. John Gribben | ASH 2017 | Major advances in immunotherapies during ASH 2017
Prof. John Gribben describes Deborah's clinical trial: venetoclax (ABT-199) plus obinutuzumab
John Gribben talks on Coronavirus
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
Meet the Editor: John G. Gribben, MD, DSc, FRCPath
Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 1)
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 3)
CAR T-cell therapy: a field moving fast
John Gribben - American Society of Hematology (ASH) conference
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 2)
